ARC and acute myeloid leukemia: ARC was variably expressed in AML patients. AML patients with low or medium ARC expression exhibited longer overall survival and longer remission duration than patients with high ARC expression. ARC was an ideal biomarker that predicted survival in AML (p = 0.00013). Moreover, ARC suppression facilitated apoptosis and enhanced the sensitivity of OCI-AML3 cells to cytosine arabinoside.